Novartis’ INSTEAD study for Onbrez® Breezhaler® in patients with moderate COPD meets primary objective
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com
Novartis announces positive results at ATS
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com Novartis announces positive results at ATS for once-daily Ultibro® Breezhaler® versus combination therapy (tiotropium plus formoterol)
KerraPro – Pressure Reducing Pads
{module [592]} {mp4remote}/images/ts-images/videos/technoline/kerrapro.mp4{/mp4remote}
Novo Nordisk Malta Medications and Devices available for Pharmacies
Insulins ACTRAPID HM 100 VIALS NOVORAPID PENFILL 3ml x 5 INSULATARD HM 100 VIALS INSULATARD HM PENFILL 3ml x 5 MIXTARD HM100 VIALS TRESIBA FLEXTOUCH 100U/ML 5 x 3ml (NEW) Needles and Devices NOVOFINE NEEDLES 30g 0.3x8mm x 100 NOVOFINE NEEDLES 31g 0.25x6mm x 100…
Tresiba (Insulin Degludec): Flexibility in day-to-day dosing time when needed
Poor glucose control in patients with diabetes can ultimately result in diabetic complications that can bedevastating for the patient’s quality of life, life-shortening, and expensive to treat for national healthcare systems.Current expert guidelines on the treatment of type 2 diabetes therefore advocate the addition of…
Tresiba® (insulin degludec): Lower risk of nocturnal hypoglycaemia vs. insulin glargine
New Tresiba® Summary of Product Characteristics: European Commission approves the label expansion to include children with type 1 and type 2 diabetes
In December 2014 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged 1-17 years with diabetes. And now, after the approval of the European…
Daflon new pack
Click to read the SPC
Servier Receives Positive CHMP Opinion for LONSURF® (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer
Recommendation is based on the RECOURSE study results demonstrating survival advantage for patients with refractory disease
Phlebolymphology
In this issue, Michel Perrin presents the first of two chapters on the updates in operative treatments for primary superficial vein incompetence. In this chapter, the various procedures for varicose vein ablation (endovenous thermal ablation, surgery, chemical ablation, mechanochemical ablation) and their possible complications are…